Dissecting the immune architecture of AML and its influence on therapeutic response identifies patients for whom immunotherapy will be most beneficial. Informing immunotherapy decisions Predicting which patients with acute myeloid leukemia (AML) are likely to respond to immunotherapy is currently di...